Moderna , Inc. (NASDAQ:MRNA) Director Noubar Afeyan has recently sold a substantial number of shares in the biotechnology company, with transactions totaling over $2.2 million. These sales occurred on June 5, 2024, and were executed at varying prices ranging from $145.91 to $154.86 per share.
The transactions, which were carried out under a pre-arranged trading plan, saw Afeyan selling shares in multiple tranches. The first batch of shares was sold at prices between $145.40 and $146.32, resulting in a weighted average price of $145.91. Subsequent sales were made at incremental price ranges, with the highest batch sold at prices from $154.47 to $155.27, culminating in a weighted average of $154.86 per share.
Following these transactions, Afeyan's direct holdings in Moderna have decreased, yet he remains a significant shareholder through indirect ownership. Notably, 8,100,794 shares are held by Flagship Ventures Fund IV, L.P., and 1,561,320 shares by Flagship Ventures Fund IV-Rx, L.P. Afeyan, as the sole manager of the general partner of these funds, disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest.
Additionally, 3,924 shares are held by Flagship Pioneering, Inc., of which Afeyan is the CEO and sole stockholder. Again, he disclaims beneficial ownership except for his pecuniary interest.
The sales were completed in accordance with Rule 10b5-1, which allows company insiders to set up a trading plan for selling stocks at a time when they are not in possession of material non-public information. This mechanism is designed to prevent any accusations of insider trading by allowing the pre-planning of transactions to occur regardless of any subsequent non-public information the insider might acquire.
Investors and followers of Moderna will be keeping a close watch on insider transaction activities as they can provide valuable insights into the company's financial health and future prospects. As of now, the company has not released any statements regarding these recent transactions.
In other recent news, Moderna has been the subject of several significant developments. Piper Sandler has reaffirmed its Overweight rating on Moderna, maintaining a price target of $214.00. Moderna's Monovalent JN.1 COVID Vaccine has received approval from the Vaccines and Related Biological Products Advisory Committee (VRBPAC) for the 2024 season. In addition, the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), slated for a market launch this fall.
Moderna's management anticipates product sales to reach at least $4.0 billion in 2024, with growth expected to resume in 2025. The company is also set to release Phase III data on its combined Flu+COVID vaccine mRNA-1083 and potential Phase III CMVictory data on mRNA-1647 within the year. The company concluded the first quarter of 2024 with a strong balance sheet, reporting $12.2 billion in cash reserves.
Furthermore, Moderna and Merck have reported a significant reduction in recurrence or death in high-risk melanoma patients from their Phase 2b clinical trial. The combination of mRNA-4157 (V940) with KEYTRUDA (pembrolizumab) resulted in a 49% reduction in risk compared to KEYTRUDA alone. Following these results, further studies have been initiated for patients with various types of cancer.
Lastly, Moderna's shares have seen an upgrade from RBC Capital Markets following the approval of its Respiratory Syncytial Virus (RSV) vaccine by regulatory authorities. The firm raised the price target to $160 from the previous $135 while maintaining an Outperform rating. Moderna anticipates making mRESVIA available for the U.S. population in time for the 2024/2025 respiratory virus season.
InvestingPro Insights
In light of the recent insider transactions at Moderna, Inc. (NASDAQ:MRNA), it's crucial for investors to consider the company's financial health and future prospects. According to InvestingPro Tips, Moderna holds more cash than debt on its balance sheet, which could be indicative of a strong financial position. Furthermore, 9 analysts have revised their earnings upwards for the upcoming period, suggesting a potential positive outlook on the company's performance.
From a data perspective, Moderna's market capitalization stands at $58.01 billion USD, reflecting the company's substantial size in the biotechnology sector. However, the company's P/E ratio is currently negative at -9.58, and it remains negative when adjusted for the last twelve months as of Q1 2024, sitting at -10.01. This suggests that investors are anticipating future growth, despite current unprofitability. Additionally, Moderna's revenue has experienced a significant decline of -65.78% over the last twelve months as of Q1 2024, which may raise concerns about sales growth.
Despite the insider sales, Moderna's stock has seen a strong return over the last three months, with a 51.8% total price return. This could indicate investor confidence in the company's long-term prospects, even if short-term challenges are present.
For those considering an investment in Moderna, or seeking to understand the full implications of the insider transactions, there are additional InvestingPro Tips available. These tips provide deeper insights and could be a valuable resource for making informed decisions. Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, and unlock the full potential of InvestingPro's offerings. There are currently 13 additional tips listed in InvestingPro for Moderna, which could help investors gauge the company's trajectory more accurately.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.